|
 |
|
|
|||
|
 |
|
Nov. 4, 2026 Source: Bayer news release Leverkusen, Germany - Bayer is operationally on track to deliver its full-year commitments at the nine-month mark, while also aiming to capitalize on improved trends as the year draws to a close. "We've reached a turning point in Pharma's growth trajectory and we're beginning to see the other side," CEO Bill Anderson said on Tuesday when presenting the company's Quarterly Statement for the third quarter. Led by Nubeqa and Kerendia, the division demonstrates its growth potential, he explained. For the full year, Bayer now expects sales growth towards the upper end of the division's guidance range. Meanwhile, Crop Science and Consumer Health are performing in line with their targets while navigating market pressures. Against this backdrop, Bayer raised its guidance for the Pharmaceuticals margin as well as Group EBITDA before special items, free cash flow and net financial debt. Bayer has also made major strides on key strategic topics. Last week, for instance, asundexian was granted approval in China for secondary stroke prevention under the brand name Sunharbo™. Describing it as "the biggest news out of our pipeline," Anderson explained that "asundexian is now the first approved Factor XIa inhibitor worldwide - and we're focused on obtaining additional approvals." Commending the team behind it, he said: "Our scientists in Wuppertal invented this molecule and have worked on it for more than a decade. They've embraced our operating model and AI, which allowed them to substantially compress the timeline, getting this medicine to patients a year early. Incredible impact!" On the litigation side, the company last week secured a decision in its favor in the first glyphosate case to go to trial since the 7-2 ruling of the U.S. Supreme Court. Anderson sees this as a strong sign that Bayer's containment work is advancing. "The fact that all 12 jurors sided with the company should be informative for those seeking to pursue claims in the court system. We will continue to handle cases in the best interests of the company, and we're awaiting an important decision on the class settlement." Crop Science: Seed business gains partly offset crop protection headwinds Sales in the agricultural business (Crop Science) came in at 3.884 billion euros, in line with the prior-year quarter on a reported basis (plus 0.7 percent). Adjusted for currency and portfolio effects, sales were 2.4 percent lower year on year, largely due to regulatory impacts and adverse weather conditions in Europe/Middle East/Africa and Asia/Pacific. However, these headwinds were partially offset by strong growth in Latin America, which was primarily fueled by increased demand for corn and soybean seeds for the summer season. Corn Seed & Traits sales came in at the prior-year level overall (Fx & portfolio adj. minus 0.1 percent), while business at Soybean Seed & Traits was up 4.5 percent (Fx & portfolio adj.). By contrast, the division registered declines of 8.6 percent (Fx & portfolio adj.) at both its Fungicides and Herbicides excl. Glyphosate units. EBITDA before special items decreased by 41.3 percent to 101 million euros in the three months ending September 30, the period which typically represents the quarter with the smallest contribution to full-year earnings of the agricultural business due to seasonal factors. The decline in earnings was mainly attributable to an increase in the cost of goods sold and higher selling expenses. These negative cost-related developments partially reflected the impact of favorable effects in the prior-year period. By contrast, there was a positive currency effect of 9 million euros. The EBITDA margin before special items decreased by 1.9 percentage points to 2.6 percent. To read the entire report click here. Tweet |
|
|
|
|
|
|
|
|
|||||||||||||
